In a session during the 2023 National Comprehensive Cancer Network Annual Conference, Deborah M. Stephens, DO, provided important updates to treatment recommendations for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, and identified key factors for selecting frontline and subsequent therapies, including immunoglobulin heavy chain variable gene status, 17p deletion/TP53 mutation status, age, patient comorbidities, and resistance mutations.
Acute lymphoblastic leukemia (ALL) is the most common cancer in pediatric patients, with an overall 5-year survival of >90%.1 The length of treatment for these patients is typically 2 to 3 years and involves several phases (induction, consolidation, and maintenance) and multiple forms of chemotherapy.
Single cord blood transplantation could be an effective treatment option for AML patients aged ≥60 years, but the risks for engraftment failure and early nonrelapse mortality should be considered.
Enasidenib Monotherapy with Addition of Azacitidine in Nonresponders Effective in Older Patients with Newly Diagnosed, IDH2-Mutated AML
Treatment with enasidenib in newly diagnosed patients with IDH2mut acute myeloid leukemia (AML) was associated with low early death and high complete response (CR)/CR with incomplete hematologic recovery rates, and yielded durable remissions.
The HARMONY Alliance: Novel Insights into Genomic Classification and Prognosis in Acute Myeloid Leukemia
A proof-of-principle study confirmed the benefit of combining large cohorts of data from patients with AML using the HARMONY Alliance platform, thus demonstrating that such “big data” can help inform individualized therapy for optimal clinical outcomes.
Characteristics and Prognostic Effects of IDH Mutations Across the Age Spectrum in AML: A Collaborative Analysis
Data from a larger cohort of patients with AML suggest IDH inhibitors may be of particular interest in older adults and patients aged >60 years, based on co-occurring NPM1 and DNMT3A mutations.
Effect of Early Blood Counts on Response and Overall SurvEffect of Early Blood Counts on Response and Overall Survival Following Glasdegib + LDAC in Newly Diagnosed AMLival Following Glasdegib + LDAC in Newly Diagnosed AML
A post-hoc analysis of data from the BRIGHT AML 1003 study showed improved overall survival associated with attaining various blood count thresholds after 1 cycle of glasdegib + LDAC versus LDAC alone in patients with newly diagnosed AML.
Venetoclax plus Standard Intensive AML Induction/Consolidation with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML
Venetoclax + FLAG-IDA was effective, elicited deep responses, and had an acceptable safety profile across multiple AML subgroups, representing an attractive option for adverse-risk newly diagnosed and relapsed/refractory AML patients, and as a bridge to allo-SCT.
Clinical Outcomes for Treatment-Naïve Patients with AML Ineligible for Intensive Chemotherapy Receiving Azacitidine or Decitabine
An analysis of outcomes for patients with treatment-naïve AML ineligible for intensive chemotherapy receiving either azacitidine or decitabine in the ASTRAL-1 study showed no significant differences in complete response (CR), overall CR, overall survival, or safety.
SAL-DaunoDouble Trial Interim Analysis: Single versus Double Induction with 7+3 for Patients with Newly Diagnosed AML
he SAL-DaunoDouble trial interim analysis suggests that, in patients with acute myeloid leukemia (AML) who respond well to a first 7+3 induction cycle of cytarabine plus anthracycline, it may be possible to omit a second induction cycle if deemed high-risk.